Pancreatic Cancer Research

GrantZIANCATS

Development of small molecule inhibitors of ULK1

Activity
ZIA
Institute
NCATS
Fiscal years counted
2018–2022
Amount counted
$1,577,156

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Abstract public domain (NIH RePORTER)

Several types of cancers, like pancreatic cancer, have been shown to be particularly dependent on autophagy for growth and survival. This project aims to develop potent, selective, and bioavailable small molecule inhibitors of ULK1, an enzyme that initiates autophagy, to enable translation of the hypothesis: autophagy inhibition via ULK1 is a valid therapeutic approach for pancreatic cancer. During this period, based on the previous work where the collaborative team performed hit-to-lead optimization the collaborator is trying to publish a paper (Selective inhibitors of autophagy reveal new link between the cell cycle and autophagy and suggest novel synergistic drug strategies) that summarizes the cell biology of autophagy inhibition, including with ULK100, a standard we synthesized.